Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 60760-972

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 60760-972). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Rab (Rabeprazole 60760 972 30)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg, packaged in a quantity of 30. The label includes multiple repeated sections listing the product name, strength, quantity, and placeholder details for lot number and expiration date. Manufactured by Rubicon Research Private Limited, India, and packaged by St. Mary's Pharmacy in Oro Valley, AZ. Instructions note to use as directed and store at controlled room temperature 15°-30°C (59°-86°F).*

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure diagram of rabeprazole sodium, showing its molecular framework including sulfur, nitrogen, oxygen atoms, and characteristic ring systems.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph showing mean heartburn scores over a 28-day study period for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. Scores range from 0 (none) to 4 (very severe), with the timeline including days before and after the start of treatment (study day 0). The graph illustrates the change in heartburn severity over time for each group.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph depicting mean heartburn scores over a study period from day -14 to day 28. Three groups are compared: placebo (n=68), rabeprazole sodium 10 mg (n=64), and rabeprazole sodium 20 mg (n=67). Heartburn scores range from 0 (none) to 4 (very severe), showing trends of decreasing scores over time after study day 0.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over time between placebo and rabeprazole sodium 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph illustrates a decrease in heartburn scores after treatment begins at day 0, with the rabeprazole line generally below placebo.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group and a group receiving 20 mg rabeprazole sodium. The x-axis represents study days, and the y-axis shows heartburn severity scores from 0 (none) to 4 (very severe). The graph depicts a decrease in heartburn scores over time for both groups, with the rabeprazole group showing generally lower scores.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.